AGT and Hypertension: A recent study using rodent models of hypertension and heart failure demonstrated that the systemic subcutaneous administration of an α‐CGRP analogue (an acylated form of α‐CGRP with extended half‐life, t1/2 = ~7h) reversed the renal, vascular, and cardiac damage caused by angiotensin II‐induced hypertension or by abdominal aortic constriction (AAC)‐induced heart failure (Aubdool et al. 2017).